Mobile

A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses...

Update Il y a 4 ans
Reference: EUCTR2004-000597-31

A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses of 5-10 mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease patients with transfusional hemosiderosis

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Evaluate the long-term safety and tolerability profile of ICL670 in sickle cell disease patients with transfusional iron overload requiring chelation therapy

Inclusion criteria

  • Sickle cell disease patients with transfusional hemosiderosis

Links